PL3007717T3 - Peptydy o antagonistycznej aktywności w stosunku do naturalnego CXCR4 - Google Patents
Peptydy o antagonistycznej aktywności w stosunku do naturalnego CXCR4Info
- Publication number
- PL3007717T3 PL3007717T3 PL14729370T PL14729370T PL3007717T3 PL 3007717 T3 PL3007717 T3 PL 3007717T3 PL 14729370 T PL14729370 T PL 14729370T PL 14729370 T PL14729370 T PL 14729370T PL 3007717 T3 PL3007717 T3 PL 3007717T3
- Authority
- PL
- Poland
- Prior art keywords
- peptides
- activities against
- against natural
- antagonistic activities
- natural cxcr4
- Prior art date
Links
- 101100441540 Xenopus laevis cxcr4-a gene Proteins 0.000 title 1
- 101100441541 Xenopus laevis cxcr4-b gene Proteins 0.000 title 1
- 230000003042 antagnostic effect Effects 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Obesity (AREA)
- AIDS & HIV (AREA)
- Toxicology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13171718 | 2013-06-12 | ||
| PCT/EP2014/062252 WO2014198834A1 (en) | 2013-06-12 | 2014-06-12 | Peptides with antagonistic activities against natural cxcr4 |
| EP14729370.8A EP3007717B1 (en) | 2013-06-12 | 2014-06-12 | Peptides with antagonistic activities against natural cxcr4 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3007717T3 true PL3007717T3 (pl) | 2018-12-31 |
Family
ID=48578924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14729370T PL3007717T3 (pl) | 2013-06-12 | 2014-06-12 | Peptydy o antagonistycznej aktywności w stosunku do naturalnego CXCR4 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10294272B2 (pl) |
| EP (1) | EP3007717B1 (pl) |
| JP (1) | JP6667435B2 (pl) |
| CN (2) | CN105530948B (pl) |
| AU (1) | AU2014280191B2 (pl) |
| CA (1) | CA2913387C (pl) |
| CY (1) | CY1120843T1 (pl) |
| DK (1) | DK3007717T3 (pl) |
| ES (1) | ES2699576T3 (pl) |
| HR (1) | HRP20181878T8 (pl) |
| LT (1) | LT3007717T (pl) |
| PL (1) | PL3007717T3 (pl) |
| PT (1) | PT3007717T (pl) |
| RS (1) | RS58164B1 (pl) |
| RU (1) | RU2671708C2 (pl) |
| SI (1) | SI3007717T1 (pl) |
| SM (1) | SMT201800589T1 (pl) |
| WO (1) | WO2014198834A1 (pl) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017217545A1 (ja) * | 2016-06-16 | 2017-12-21 | 国立大学法人東京大学 | プレキシンの結合調節剤 |
| CA3072009A1 (en) * | 2017-09-08 | 2019-03-14 | Neopep Pharma Gmbh & Co. Kg | Crcx4 inhibitor peptides for the treatment of diseases |
| CN113286806A (zh) * | 2018-11-09 | 2021-08-20 | 尼欧派普制药有限两合公司 | 治疗压力、免疫反应和中风综合征的多肽 |
| EP3872084A1 (en) | 2020-02-27 | 2021-09-01 | Universität Ulm | Epi-x4 based peptides and derivatives thereof |
| WO2023099725A1 (de) * | 2021-12-02 | 2023-06-08 | Pharis Biotec Gmbh | Pharmazeutische zubereitung enthaltend eine mischung eines natriuretischen peptids (anp) und eines peptidischen hemmstoffs des cxcr4-rezeptors |
| WO2024235986A1 (en) | 2023-05-15 | 2024-11-21 | Pharis Biotec Gmbh | Peptides for use in the treatment of sarcoma |
| EP4483892A1 (en) * | 2023-06-29 | 2025-01-01 | Pharis Biotec GmbH | Composition comprising lekti polypeptides for the treatment of disorders |
| EP4501347A1 (en) | 2023-08-02 | 2025-02-05 | Wolf-Georg Forssmann | Peptides for use in the treatment of central nervous system disorders |
| EP4501348A1 (en) | 2023-08-02 | 2025-02-05 | Wolf-Georg Forssmann | Peptides for use in the improvement of well-being |
| WO2025114560A1 (en) | 2023-12-01 | 2025-06-05 | Pharis Biotec Gmbh | Alb408-423 peptides for use in the treatment of cancer in combination with radiotherapy |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1111540C (zh) | 1993-06-09 | 2003-06-18 | 康诺特实验室有限公司 | 串联的合成hiv－1肽类 |
| EP0967284A1 (en) * | 1998-05-28 | 1999-12-29 | Pfizer Limited | Phosphodiesterases |
| US20030220482A1 (en) * | 2000-02-03 | 2003-11-27 | Ziwei Huang | Novel peptide antagonist of CXCR4 derived from the N-terminus of the viral chemokine vMIP-II |
| US7390870B2 (en) * | 2001-07-03 | 2008-06-24 | Posco | Immune-enhancing peptides |
| AU2002364240A1 (en) | 2002-06-28 | 2004-01-19 | Foamex L.P. | Gas diffusion layer for fuel cells |
| WO2004094465A2 (en) * | 2003-04-23 | 2004-11-04 | The Board Of Trustees Of The University Of Illinois Office Of Technology Management University Of Illinois At Urbana-Champaign | Synthetic molecules that mimic chemokines |
| AP2081A (en) * | 2004-06-18 | 2010-01-04 | Ipf Pharmaceuticals Gmbh | Oligomeric peptides and their use for the treatment of HIV infections |
| FR2877946B1 (fr) * | 2004-11-12 | 2011-02-11 | Commissariat Energie Atomique | Peptides derives de la maurocalcine utilisables comme vecteurs pour l'adressage intracellulaire de molecules d'interet |
| US20110143992A1 (en) * | 2006-02-13 | 2011-06-16 | Dennis Taub | Methods and Compositions Related to GHS-R Antagonists |
| EP2368908A3 (en) * | 2006-11-10 | 2011-10-12 | CovX Technologies Ireland Limited | Anti- angiogenic compounds |
| DE102007030904A1 (de) * | 2007-07-03 | 2009-02-05 | Pharis Biotec Gmbh | Humanes zirkulierendes antivirales Albumin-Fragment (ALB-408) und seine Verwendung |
| KR101722961B1 (ko) * | 2009-02-11 | 2017-04-04 | 알부메딕스 에이/에스 | 알부민 변이체 및 접합체 |
| KR20130020765A (ko) | 2010-02-16 | 2013-02-28 | 메디뮨 엘엘씨 | Ｈｓａ-관련 조성물 및 사용방법 |
| CN103379915A (zh) | 2011-02-15 | 2013-10-30 | 米迪缪尼有限公司 | Hsa相关组合物及使用方法 |
| EP2564869A1 (en) * | 2011-09-02 | 2013-03-06 | Ceva Sante Animale | Synthetic capsid proteins and uses thereof |
-
2014
- 2014-06-12 SM SM20180589T patent/SMT201800589T1/it unknown
- 2014-06-12 DK DK14729370.8T patent/DK3007717T3/da active
- 2014-06-12 CA CA2913387A patent/CA2913387C/en active Active
- 2014-06-12 ES ES14729370T patent/ES2699576T3/es active Active
- 2014-06-12 US US14/896,249 patent/US10294272B2/en active Active
- 2014-06-12 SI SI201430966T patent/SI3007717T1/sl unknown
- 2014-06-12 PT PT14729370T patent/PT3007717T/pt unknown
- 2014-06-12 CN CN201480033321.XA patent/CN105530948B/zh active Active
- 2014-06-12 CN CN202010681852.7A patent/CN111875670A/zh active Pending
- 2014-06-12 JP JP2016518492A patent/JP6667435B2/ja active Active
- 2014-06-12 EP EP14729370.8A patent/EP3007717B1/en active Active
- 2014-06-12 AU AU2014280191A patent/AU2014280191B2/en not_active Ceased
- 2014-06-12 RU RU2015151872A patent/RU2671708C2/ru active
- 2014-06-12 RS RS20181430A patent/RS58164B1/sr unknown
- 2014-06-12 HR HRP20181878TT patent/HRP20181878T8/hr unknown
- 2014-06-12 WO PCT/EP2014/062252 patent/WO2014198834A1/en not_active Ceased
- 2014-06-12 LT LTEP14729370.8T patent/LT3007717T/lt unknown
- 2014-06-12 PL PL14729370T patent/PL3007717T3/pl unknown
-
2018
- 2018-11-09 CY CY181101190T patent/CY1120843T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI3007717T1 (sl) | 2018-12-31 |
| US20160122389A1 (en) | 2016-05-05 |
| JP6667435B2 (ja) | 2020-03-18 |
| ES2699576T3 (es) | 2019-02-11 |
| AU2014280191B2 (en) | 2018-10-11 |
| RU2015151872A (ru) | 2017-07-17 |
| EP3007717A1 (en) | 2016-04-20 |
| RS58164B1 (sr) | 2019-03-29 |
| EP3007717B1 (en) | 2018-08-29 |
| SMT201800589T1 (it) | 2019-01-11 |
| HRP20181878T8 (hr) | 2019-03-08 |
| US10294272B2 (en) | 2019-05-21 |
| CA2913387A1 (en) | 2014-12-18 |
| CN111875670A (zh) | 2020-11-03 |
| CN105530948A (zh) | 2016-04-27 |
| CN105530948B (zh) | 2023-05-26 |
| AU2014280191A1 (en) | 2015-12-17 |
| LT3007717T (lt) | 2018-11-26 |
| JP2016521716A (ja) | 2016-07-25 |
| RU2671708C2 (ru) | 2018-11-06 |
| HRP20181878T1 (hr) | 2019-01-11 |
| CY1120843T1 (el) | 2019-12-11 |
| CA2913387C (en) | 2024-05-21 |
| DK3007717T3 (da) | 2019-01-02 |
| WO2014198834A1 (en) | 2014-12-18 |
| PT3007717T (pt) | 2018-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2508037B (en) | Chair | |
| AU355185S (en) | Chair | |
| ZA201505966B (en) | Peptides and compositions | |
| SMT201800589T1 (it) | Peptidi con attivita' antagoniste contro cxcr4 naturale | |
| GB201305277D0 (en) | Novel combination and use | |
| SI3087092T1 (sl) | Protimikrobni peptid in njega uporaba | |
| AU351025S (en) | Chair | |
| GB2520812B (en) | Lift-recliner chair | |
| PT2855506T (pt) | Péptido e utilização do mesmo | |
| PL2910131T3 (pl) | Kompozycja przeciwdziałająca zmęczeniu i jej zastosowanie | |
| GB201307989D0 (en) | Novel combinations and use | |
| GB201308122D0 (en) | Chair | |
| AU353456S (en) | Hammock | |
| GB201313405D0 (en) | Hammock | |
| AU352787S (en) | Chair | |
| AU352785S (en) | Chair | |
| AU352786S (en) | Chair | |
| AU352853S (en) | Chair | |
| PH32013001221S1 (en) | Chair | |
| PH32013001222S1 (en) | Chair | |
| PH32013001223S1 (en) | Chair | |
| PH32013001227S1 (en) | Chair | |
| AU350353S (en) | Chair | |
| AU350355S (en) | Chair | |
| AU350354S (en) | Chair |